What we do Ipca Laboratories Ltd is a global pharmaceutical company manufacturing and marketing over 350 formulations and 80 active pharmaceutical ingredients in more than 100 countries. |
Founded in 1,949 |
Market share Ranks 16th in Indian domestic formulations; major global supplier of APIs and formulations with a strong export presence. |
Problem solved Provides affordable, high-quality medicines addressing cardiovascular, anti-malarial, pain management, and other health needs worldwide. |
Top clients or who we serve Supplies multinational pharma companies and markets branded generics; serves B2B and B2C clients globally. |
Key management Ajit Kumar Jain (Managing Director), Pranay Godha (Managing Director/CEO), Premchand Godha (Executive Chairman). |
Our journey and innovations Founded in 1949; pioneered sugarcoated chloroquine; expanded R&D; multiple acquisitions and global regulatory approvals including USFDA. |
Where we operate Operates extensively across India, Europe, Africa, Americas, Asia, CIS, and Australasia via subsidiaries and direct marketing. |
Top products or what we offer Flagship APIs like Atenolol, Chloroquine Phosphate, diverse formulations including Perinorm and Bromhexine. |
Top brands Perinorm, Isordil, Activa; six brands rank among India's top 300 formulations; diversified portfolio driving revenues. |
Raw materials needed Basic chemical raw materials and intermediates for API and formulation manufacturing. |
Raw materials supplier Sourced globally from chemical raw material providers and in-house production units. |
Recurring vs cyclical contribution Majority recurring revenue from formulations and API sales with steady global demand. |
Our industry position Third largest in India by volume; significant player in global generic API supply and branded formulations. |
Financial highlights FY 2024-25 consolidated revenue ₹9032 crore (+15% YoY), net profit ₹788 crore (+49% YoY), strong profitability and cash flows. |
Geographical revenue split India ₹4042 crore; Outside India ₹4898 crore with strong growth in Europe, Americas, and Africa markets. |
Order book - |
Whats driving growth Innovation, geographic expansion, existing and new product launches supported by regulatory approvals and acquisitions. |
Our future plans Setting up new manufacturing plants including mAbs, drug intermediates, injectables across India and USA by 2025-26. |
Our green promise Committed to safety, environment and health with employee training and sustainable manufacturing practices. |
Our people and values Over 18,000 employees globally with focus on training, inclusion and meritocratic culture. |
Key challenges ahead Regulatory challenges, geopolitical risks, input cost inflation, and transitioning to high-value formulations. |
Interesting facts One of the first Indian firms to launch sugarcoated chloroquine; recognized twice by Forbes 'Best under a Billion'. |
Risks and strategy Mitigates risks via robust R&D, diverse markets, regulatory compliance and strategic acquisitions. |
